Genzyme's Mozobil receives CHMP endorsement
This article was originally published in Scrip
Executive Summary
The EU's CHMP has recommended the marketing approval of Genzyme's stem cell transplantation primer Mozobil (plerixafor), for use in combination with granulocyte-colony stimulating factor (G-CSF) to mobilise haematopoietic stem cells from the bone marrow into the bloodstream for collection and subsequent autologous transplantation in patients with lymphoma and multiple myeloma.